Compass Therapeutics, Inc. (CMPX)Healthcare | Biotechnology | Boston, United States | NasdaqCM
2.26 USD
-0.07
(-3.004%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:45 a.m. EDT
Compass Therapeutics presents a classic biotech binary play where the narrative is currently decoupled from the hard data. While the company boasts a fortress-like balance sheet with massive cash reserves relative to debt and a 'strong buy' analyst consensus based on potential pipeline milestones, the stock has suffered a brutal structural decline, dropping nearly half its value over the last four years. This multi-year downtrend suggests the market has priced in significant execution risks or failed trials that outweigh the current hype. The recent news of a 200% year-over-year gain appears to be a technical rebound off lows rather than a fundamental turnaround, especially given the trailing losses and negative free cash flow. The options market confirms this tension: traders are buying cheap calls hoping for a clinical breakthrough to drive a massive spike, but they are also hedging heavily with puts, anticipating that the upcoming trial results could fail or lead to a sharp correction. Until the clinical data resolves this binary outcome, the investment case remains speculative; the strong fundamentals provide a safety floor, but the lack of sustained growth and the volatile price action prevent a confident long-term recommendation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.826447 |
| AutoETS | 0.844547 |
| AutoARIMA | 0.849807 |
| MSTL | 0.850153 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 1.17 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.251 |
| Market Cap | 406,998,688 |
| Forward P/E | -4.89 |
| Beta | 0.75 |
| Website | https://www.compasstherapeutics.com |
As of July 11, 2026, 6:45 a.m. EDT: Speculators are positioning for a binary event driven by upcoming clinical data. Call volume is heavily skewed toward out-of-the-money strikes ($3.00 and $4.00), indicating a bullish bet on a successful trial outcome. However, put volume is concentrated in the immediate term (July/August) with significant open interest at strikes above the current price, suggesting a hedge against potential disappointment or a 'sell the news' scenario. The imbalance in July shows more call volume than put volume, while longer-dated expirations show a mix, reflecting uncertainty on whether the catalyst will be a catalyst or a contraindication.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24161077 |
| Address1 | 80 Guest Street |
| Address2 | Suite 601 |
| All Time High | 11.0 |
| All Time Low | 0.765 |
| Ask | 2.81 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,826,290 |
| Average Daily Volume3 Month | 8,123,134 |
| Average Volume | 8,123,134 |
| Average Volume10Days | 2,826,290 |
| Beta | 0.753 |
| Bid | 1.65 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.035 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.26 |
| Current Ratio | 19.038 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.31 |
| Day Low | 2.185 |
| Debt To Equity | 5.251 |
| Display Name | Compass Therapeutics |
| Earnings Call Timestamp End | 1,754,913,600 |
| Earnings Call Timestamp Start | 1,754,913,600 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,777,984,200 |
| Earnings Timestamp Start | 1,777,984,200 |
| Ebitda | -75,021,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.961 |
| Enterprise Value | 222,102,688 |
| Eps Current Year | -0.43417 |
| Eps Forward | -0.4625 |
| Eps Trailing Twelve Months | -0.4 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.062 |
| Fifty Day Average Change | 0.19799995 |
| Fifty Day Average Change Percent | 0.096023254 |
| Fifty Two Week Change Percent | -24.161076 |
| Fifty Two Week High | 6.88 |
| Fifty Two Week High Change | -4.62 |
| Fifty Two Week High Change Percent | -0.6715116 |
| Fifty Two Week Low | 1.61 |
| Fifty Two Week Low Change | 0.65 |
| Fifty Two Week Low Change Percent | 0.4037267 |
| Fifty Two Week Range | 1.61 - 6.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,617,629,400,000 |
| Float Shares | 122,693,896 |
| Forward Eps | -0.4625 |
| Forward P E | -4.8864865 |
| Free Cashflow | -30,043,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 39 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12455 |
| Held Percent Institutions | 0.94203 |
| Implied Shares Outstanding | 180,087,915 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-11-02 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts. |
| Long Name | Compass Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 406,998,688 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_266166780 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -68,173,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 406,998,687 |
| Number Of Analyst Opinions | 12 |
| Open | 2.29 |
| Operating Cashflow | -53,204,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 500 8099 |
| Pre Market Change | 0.0 |
| Pre Market Change Percent | 0.0 |
| Pre Market Price | 2.26 |
| Pre Market Time | 1,784,032,203 |
| Previous Close | 2.33 |
| Price Eps Current Year | -5.205334 |
| Price Hint | 4 |
| Price To Book | 2.183575 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.94 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | -0.0699999 |
| Regular Market Change Percent | -3.00429 |
| Regular Market Day High | 2.31 |
| Regular Market Day Low | 2.185 |
| Regular Market Day Range | 2.185 - 2.31 |
| Regular Market Open | 2.29 |
| Regular Market Previous Close | 2.33 |
| Regular Market Price | 2.26 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,875,795 |
| Return On Assets | -0.27914 |
| Return On Equity | -0.45946 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 180,087,915 |
| Shares Percent Shares Out | 0.2062 |
| Shares Short | 37,138,819 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 33,270,343 |
| Short Name | Compass Therapeutics, Inc. |
| Short Percent Of Float | 0.2465 |
| Short Ratio | 9.75 |
| Source Interval | 15 |
| State | MA |
| Symbol | CMPX |
| Target High Price | 24.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 8.5 |
| Target Median Price | 6.5 |
| Total Cash | 194,687,008 |
| Total Cash Per Share | 1.081 |
| Total Debt | 9,791,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.33495 |
| Two Hundred Day Average Change | -2.07495 |
| Two Hundred Day Average Change Percent | -0.47865602 |
| Type Disp | Equity |
| Volume | 1,875,795 |
| Website | https://www.compasstherapeutics.com |
| Zip | 2,135 |